@article {Young-Xu2021.09.27.21264194, author = {Yinong Young-Xu and Jeremy Smith and Caroline Korves}, title = {SARS-Cov-2 Infection versus Vaccine-Induced Immunity among Veterans}, elocation-id = {2021.09.27.21264194}, year = {2021}, doi = {10.1101/2021.09.27.21264194}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background With over 40 million cases of SARS-CoV-2 infection reported in the US and discussion of both vaccine mandates as well as boosters ongoing, we aim to examine protection conferred by previous infection compared with vaccination so that citizens and policy makers can make informed decisions.Objectives To compare mRNA COVID-19 vaccine-induced immunity against immunity induced by previous infection with SARS-CoV-2 between June and August 2021 when the Delta variant became dominant in the US.We conducted a retrospective observational study comparing two groups whose incident vaccination or infection occurred within the first two months of 2021: (1) SARS-CoV-2-naive individuals who received a full mRNA vaccination - 2 doses of either Pfizer or Moderna vaccine, (2) newly infected individuals who were subdivided into those have not been vaccinated and those have been vaccinated after their infection. Matched multivariable Cox proportional hazards model was applied. We evaluated laboratory (RT-PCR) confirmed SARS-CoV-2 infection during follow-up, COVID-related hospitalization, and deaths.Setting Veterans Health Administration (VHA).Main outcomes Positive SARS-CoV-2 PCR test, COVID-related hospitalization, and deaths. Protection was estimated from hazard ratios with 95\% confidence intervals (CI).Results A total of 9,539 patients with SARS-CoV-2 infection during the first two months of 2021 were matched to 14,458 and 23,105 patients fully vaccinated with Moderna and Pfizer mRNA vaccines, during the same two months. 3,917 (41\%) of patients with SARS-CoV-2 infection were subsequently vaccinated. We plan to study this group separately. Consequently, protections were estimated among those with infection but were not subsequently vaccinated and those vaccinated with a mRNA vaccine. Among seniors, Moderna and Pfizer mRNA vaccines offered stronger protection against infection, lowering the risk by an additional 66\% [HR: 0.34 (95\% CI, 0.14-0.78)] and 68\% [HR: 0.32 (95\% CI, 0.14-0.70)]; stronger protection against hospitalization, lowering the risk by an additional 61\% [HR: 0.34 (95\% CI, 0.14-0.78)] and 45\% [HR: 0.34 (95\% CI, 0.14-0.78)]; and stronger protection against deaths lowering the risk by an additional 95\% [HR: 0.05 (95\% CI, 0.004-0.62)] and 99\% [HR: 0.01 (95\% CI, 0.001-0.44)]. Among young adults (age \< 65), the protections offered by vaccines were statistically equivalent to that provided by previous infection, especially in terms of absolute incidence rate.Conclusions Among the elderly (age 65 or older), two-dose mRNA vaccines provided stronger protection against infection, hospitalization, and death, compared to natural immunity. Among young adults (age \< 65), the protections offered between natural immunity and vaccine-induced immunity were similar.Competing Interest StatementConflict of Interest Declaration: The authors, YYX, JS, and CK acknowledge having received funding from Pfizer outside this research project.Funding StatementThis project was funded by the U.S. Department of Veterans Affairs (VA) Office of Rural Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the institutional review board of the VA Medical Center in White River Junction, VT and was granted a waiver of consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request to the lead author.}, URL = {https://www.medrxiv.org/content/early/2021/09/29/2021.09.27.21264194}, eprint = {https://www.medrxiv.org/content/early/2021/09/29/2021.09.27.21264194.full.pdf}, journal = {medRxiv} }